Home / 510(k) Clearances / K202304

510(k) K202304

NYU Langone Genome PACT (Genome Profiling of Actionable Cancer Targets) by Nyu Langone Medical Center — Product Code PZM

Clearance Details

Decision
SESE (Substantially Equivalent)
Decision Date
July 14, 2021
Date Received
August 14, 2020
Clearance Type
Traditional
Expedited Review
No
Third Party Review
Yes

Device Classification

Device Name
Next Generation Sequencing Based Tumor Profiling Test
Device Class
Class II
Regulation Number
866.6080
Review Panel
PA
Submission Type

A next-generation sequencing based tumor profiling test is a qualitative in vitro diagnostic test intended to detect mutations in a broad panel of targeted genes that are somatically altered in malignant neoplasms from tumor specimens obtained from patients diagnosed with malignant solid neoplasms using targeted next-generation sequencing.

Other clearances for product code PZM

  • K241868 — xR IVD (September 19, 2025)
  • K250003 — GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS6005) (August 29, 2025)
  • K210017 — ACTOnco, ACTOnco IVD (December 23, 2022)
  • K192063 — PGDx elio tissue complete (April 24, 2020)
  • K190661 — Omics Core (November 9, 2019)
  • DEN170058 — MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybrid (November 15, 2017)